中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 9
Sep.  2016
Turn off MathJax
Article Contents

A new understanding of etiological treatment in patients with severe viral hepatitis

DOI: 10.3969/j.issn.1001-5256.2016.09.002
Research funding:

 

  • Published Date: 2016-09-20
  • Severe viral hepatitis has a various etiology,which varies greatly among different regions. Hepatitis B and hepatitis C are commonly seen in China. It has been proved that antiviral therapy has great significance in HBV- related severe liver disease,and they often need long- term or lifetime medication. The selection of drugs should consider potency,low resistance,and safety. Patients with renal insufficiency should use nucleoside analogues with a note of caution. As for patients with HBV infection who plan to use or have already used immunosuppressants,antiviral therapy is of vital importance. Current studies support the therapeutic regimen with direct- acting antiviral agents in patients with severe hepatitis complicated by chronic renal disease. This therapy has achieved a satisfactory effect,but such patients tend to have a higher recurrence rate than general patients. Therefore,more large- scale clinical studies which last for a longer time are needed for validation. In conclusion,effective antiviral therapy should be given with reference to detailed condition,so as to improve the survival rates in patients with severe viral liver disease.

     

  • loading
  • [1]WANG YM,TANG B.Interpretation and diagnostic advances in the new version of diagnostic and treatment guidelines for liver failure in2012[J].Chin Hepatol,2013,18(4):245-248.(in Chinese)王宇明,汤勃.2012年新版《肝衰竭诊治指南》诊断进展的解读与探讨[J].肝脏,2013,18(4):245-248.
    [2]GALLEGOS-OROZCO JF,RAKELA-BRODNER J.Hepatitis viruses:not always what it seems to be[J].Rev Med Chil,2010,138(10):1302-1311.
    [3]YOU S,RONG Y,ZHU B,et al.Changing etiology of liver failure in 3,916 patients from northern China:a 10-year survey[J].Hepatol Int,2013,7(2):714-720.
    [4]LIU C,WANG YM,FAN K.Epidemiological and clinical features of hepatitis B virus related liver failure in China[J].Word J Gastroenterol,2011,17(25):3054-3059.
    [5] Liver Failure and Artificial Liver Group,Chinese Society of Infectious Diseases,CMA;Severe Liver Diseases and Artificial Liver Group,Chinese Society of Hepatology,CMA.Guideline for diagnosis and treatment of liver failure(2012 version)[J].Chin J Clin Infect Dis,2012,5(6):321-327.(in Chinese)中华医学会感染病学分会肝衰竭与人工肝治疗组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南(2012年版)[J].中华临床感染病杂志,2012,5(6):321-327.
    [6]SARIN SK,KEDARISETTY CK,ABBAS Z,et al.Acute-on-chronic liver failure:consensus recommendations of the Asian Pacific Association for the Study of the Liver(APASL)2014[J].Hepatol Int,2014,8(4):453-471.
    [7]TERRAULT NA,BZOWEJ NH,CHANG KM,et al.AASLD guidelines for treatment of chronic hepatitis B[J].Hepatology,2016,63(1):261-283.
    [8]WANG YM.Application of anti-hepatitis B virus therapy in liver failure[J].Chin J Pract Intern Med,2014,34(6):549-552.(in Chinese)王宇明.抗病毒治疗在乙型肝炎相关性肝衰竭中的应用[J].中国实用内科杂志,2014,34(6):549-552.
    [9] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1941-1960.
    [10]CHEN CH,LIN CL,HU TH,et al.Entecavir vs.lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation[J].J Hepatol,2014,60(6):1127-1134.
    [11]GARG H,SARIN SK,KUMAR M,et al.Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure[J].Hepatology,2011,53(3):774-780.
    [12]ZHAO H,WANG GS,XIE W,et al.Efficacy of entecavir on liver failure patients with chronic hepatitis B[J/CD].Chin J Exp Clin Infect Dis:Electronic Edition,2011,5(2):40-43.(in Chinese)赵红,王桂爽,谢雯,等.恩替卡韦治疗慢性乙型肝炎肝衰竭的疗效观察[J/CD].中华实验和临床感染病杂志:电子版,2011,5(2):40-43.
    [13]ZHANG Y,ZHENG S,ZHOU JJ,et al.Efficacy of lamivudine in treatment on HBV-related liver failure:Meta analysis study[J].J Third Milit Med Univ,2008,30(9):848-850.(in Chinese)张耀,郑莎,周吉军,等.拉米夫定治疗乙型肝炎病毒相关性肝衰竭疗效的Meta分析[J].第三军医大学学报,2008,30(9):848-850.
    [14]LOPEZ-SERRANO P,de la FUENTE BRIONGOS E,ALONSO EC,et al.Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases:when and how to apply prophylaxis,with a special focus on corticoste therapy[J].World J Hepatol,2015,7(3):539-547.
    [15]di BISCEGLIE AM,LOK AS,MARTIN P,et al.Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs:just the tip of the iceberg?[J].Hepatology,2015,61(2):703-711.
    [16]REDDY KR,BEAVERS KL,HAMMOND SP,et al.American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy[J].Gastroenterology,2015,148(1):215-219.
    [17]FOSTER GR,PIANKO S,BROWN A,et al.Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection[J].Gastroenterology,2015,149(6):1462-1470.
    [18]FOSTER GR,IRVING WL,CHEUNG MC,et al.Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis[J].J Hepatol,2016,64(6):1224-1231.
    [19]SARRAZIN C.The importance of resistance to direct antiviral drugs in HCV infection in clinical practice[J].J Hepatol,2016,64(2):486-504.
    [20]BENITEZ-GUTIERREZ L,BARREIRO P,LABARGA P,et al.Prevention and management of treatment failure to new oral hepatitis C drugs[J].Expert Opin Pharmacother,2016,17(9):1215-1223.
    [21]AASLD/IDSA HCV Guidance Panel.Hepatitis C guidance:AASLD-IDSA recommendations for testing,managing,and treating adults infected with hepatitis C virus[J].Hepatology,2015,62(3):932-954.
    [22]European Association for Study of Liver.EASL recommendations on treatment of hepatitis C 2015[J].J Hepatol,2015,63(1):199-236.
    [23] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for hepatitis C:a 2015 update[J].J Clin Hepatol,2015,31(12):1961-1979.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.丙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1961-1979.
    [24]HARTMAN J,BICHOUPAN K,PATEL N,et al.Re-re-treatment of hepatitis C virus:eight patients who relapsed twice after direct-acting-antiviral drugs[J].World J Gastroenterol,2015,21(43):12430-12438.
    [25]VERNA EC,SHETTY K,LUKOSE T,et al.High post-transplant virological response in hepatitis C virus infected patients treated with pretransplant protease inhibitor-based triple therapy[J].Liver Int,2015,35(2):510-517.
    [26]DETERDING K,HONER ZU SIEDERDISSEN C,PORT K,et al.Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies[J].Aliment Pharmacol Ther,2015,42(7):889-901.
    [27]CHARLTON M,EVERSON GT,FLAMM SL,et al.Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease[J].Gastroenterology,2015,149(3):649-659.
    [28]MANNS M,SAMUEL D,GANE EJ,et al.Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease:a multicentre,open-label,randomised,phase 2 trial[J].Lancet Infect Dis,2016,16(6):685-697.
    [29]POORDAD F,SCHIFF ER,VIERLING JM,et al.Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence[J].Hepatology,2016,63(5):1493-1505.
    [30]HONER ZU SIEDERDISSEN C,MAASOUMY B,DETERDING K,et al.Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world setting[J].Liver Int,2015,35(7):1845-1852.
    [31]CONTI F,BUONFIGLIOLI F,SCUTERI A,et al.Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals[J].J Hepatol,2016.[Epub ahead of print]
    [32]ISNARD BAGNIS C,CACOUB P.Hepatitis C therapy in renal patients:who,how,when?[J].Infect Dis Ther,2016.[Epub ahead of print]
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (1996) PDF downloads(548) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return